NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/23/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization19,623 mln
Float168 mln
Earnings Date08/04/2026
EPS
7.07
Strong
P / E
14.77
Fair value
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-2.48
Borderline
1-Year Forecast
109
Fairly priced
Relative Strength
78
/ 100
Strongly outperforming
Business Description
Incyte Corporation is a biopharmaceutical company founded in 1991 and based in Wilmington, Delaware, that discovers, develops, and sells treatments for cancers and other serious diseases across the United States, Europe, Canada, and Japan. The company markets several approved medicines targeting blood cancers, lymphomas, and graft-versus-host disease, while also advancing a broad pipeline of experimental treatments for conditions ranging from ovarian cancer to rare inflammatory diseases. Incyte works alongside partners such as Novartis, Lilly, and Syndax, and distributes its products through specialty pharmacies, hospital pharmacies, and distributors.